Francesca Bargiacchi, PhD’s Post

Although the USPSTF guidelines have changed once again, there are no new trials that have prompted this change. The same data is being analyzed and re-analyzed. There is no ability to personalize screening recommendations based on risk for specific tumor types nor to customize prevention recommendations. We need new trials and new data instead of rehashing the same data. We hope that the WISDOM study results can inform our approach- we are still a year away from first results.   The WISDOM Study is a clinical study designed to advance our tools for risk assessment in order to personalize screening and risk reduction for breast cancer. We are using the full spectrum of existing and emerging risk factors, including a full understanding of the contribution of inherited genes (mutations as well as the combination of genes that can help us predict the risk for fast and slow growing cancers). In WISDOM 2.0 we are working to bring in mammographic AI as it becomes available. WISDOM is an opportunity to get (free) access to the best available data and tools, and to generate the information to create better and more modern and informed guidelines in the future. Join us today! https://lnkd.in/g3qpj4mX

We're extremely honored to share that Relay Therapeutics has been named this year's #1 Place to Work in Massachusetts for Large Companies by Boston Globe Media. Our distinguished approach, uniquely collaborative people, and drive to help patients make up a culture owned by each of our employees. #workboston